Projects per year
Personal profile
Biography
Professor Howard Gurney is the Director of Clinical Trials for the Faculty of Medicine and Health Sciences at Macquarie University.
Professor Gurney has a firm background in clinical research and has subspecialty interests in urogenital cancers including prostate, bladder, testis and kidney cancer.
He has been the principal investigator for over 100 clinical trials and has published over 100 peer-reviewed articles in journals and book chapters. Current research interests include the pharmacogenomics and therapeutic monitoring of chemotherapy and targeted therapies and he has published widely in this area. He is regarded as a leading authority on mechanisms for safe dosing of anticancer agents and has held research grants and has written a number of invited editorials on these topics.
Fingerprint Dive into the research topics where Howard Gurney is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 6 Similar Profiles
Renal Cell Carcinoma
Medicine & Life Sciences
Prostatic Neoplasms
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Drug Therapy
Medicine & Life Sciences
Castration
Medicine & Life Sciences
docetaxel
Medicine & Life Sciences
Neoplasms
Medicine & Life Sciences
Survival
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2013 2024
A phase 1/2 open label, multi-center dose escalation and expansion study of combination immunotherapy CBT-501 (anti-PD-1) or nivolumab with CBT-101 (c-Met inhibitor) in locally advanced or metastatic hepatocellular carcinoma and renal cell carcinoma
Sabanathan, D., Chapman, N., Butala, R. & Gurney, H.
16/05/19 → 15/05/24
Project: Other
MISC_UniCanberra: Research into and Testing of Epigenetic based Biomarkers and companion therapeutics.
Gurney, H. & Cunningham, J.
1/04/19 → 30/04/20
Project: Other
A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients with Previously Untreated Advanced Renal Cell Carcinoma
Gurney, H., Chapman, N. & Butala, R.
28/02/19 → 27/02/24
Project: Other
Misc_Novotech: A Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Study Comparing CB‐839 in Combination with Cabozantinib (CB‐Cabo) vs. Placebo with Cabozantinib (Pbo‐Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Gurney, H. & Cunningham, J.
17/07/18 → 5/06/23
Project: Other
MISC_Covance Chiltern: A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting Programmed Death Ligand 1 (PD-L1) Protein in Patients with Advanced Solid Tumors
Gurney, H., Butala, R. & Cunningham, J.
16/07/18 → 15/07/23
Project: Other
Research Outputs 1987 2019
A potent liver-mediated mechanism for loss of muscle mass during androgen deprivation therapy
Lam, T., McLean, M., Hayden, A., Poljak, A., Cheema, B., Gurney, H., Stone, G., Bahl, N., Reddy, N., Shahidipour, H. & Birzniece, V., 1 May 2019, In : Endocrine Connections. 8, 5, p. 605-615 11 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access
File
Androgens
Urea
Muscles
Liver
Testosterone
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Rini, B. I., Powles, T., Atkins, M. B., Escudier, B., McDermott, D. F., Suarez, C., Bracarda, S., Stadler, W. M., Donskov, F., Lee, J. L., Hawkins, R., Ravaud, A., Alekseev, B., Staehler, M., Uemura, M., De Giorgi, U., Mellado, B., Porta, C., Melichar, B., Gurney, H. & 12 others, 15 Jun 2019, In : The Lancet. 393, 10189, p. 2404-2415 12 p.Research output: Contribution to journal › Article › Research › peer-review
Renal Cell Carcinoma
Randomized Controlled Trials
Disease-Free Survival
Ligands
Research Personnel
Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., Lee, J. L., Vasiliev, A., Miller, W. H., Gurney, H., Schmidinger, M., Larkin, J., Atkins, M. B., Bedke, J., Alekseev, B., Wang, J. & 8 others, 21 Mar 2019, In : New England Journal of Medicine. 380, 12, p. 1103-1115 13 p.Research output: Contribution to journal › Article › Research › peer-review
Renal Cell Carcinoma
Disease-Free Survival
sunitinib
avelumab
axitinib
Bioanalytical evaluation of dried plasma spots for monitoring of abiraterone and ∆(4)-abiraterone from cancer patients
Bhatnagar, A., McKay, M. J., Thaysen-Andersen, M., Arasaratnam, M., Crumbaker, M., Gurney, H. & Molloy, M. P., 15 Sep 2019, In : Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 1126-1127, p. 1-9 9 p., 121741.Research output: Contribution to journal › Article › Research › peer-review
Plasmas
Monitoring
Neoplasms
Drug Monitoring
Castration
Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer
Al-Mansouri, L. & Gurney, H., 1 Dec 2019, In : Asia-Pacific Journal of Clinical Oncology. 15, 6, p. 288-295 8 p.Research output: Contribution to journal › Review article › Research › peer-review
Castration
Prostatic Neoplasms
docetaxel
Drug Therapy
Taxoids